Skip to main content
main-content
Erschienen in: Herz 1/2020

26.04.2018 | Original articles

Diagnostic value of novel biomarkers for heart failure

A meta-analysis

verfasst von: Z. Huang, J. Zhong, Y. Ling, Y. Zhang, W. Lin, L. Tang, J. Liu, S. Li

Erschienen in: Herz | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The present meta-analysis examined the diagnostic value of novel biomarkers for heart failure (HF), including copeptin, galectin-3, hs-cTnT, MR-proANP, MR-proADM, and ST2.

Methods

English (EMBASE, Cochrane, and PubMed) and Chinese (Wanfang data, CNKI, SinoMed) databases were searched to identify suitable studies that were published before 1 December 2016. Data were extracted using standard forms. Pooled diagnostic statistics were calculated using DerSimonian–Laird random-effects models.

Results

The analysis comprised 45 studies. The pooled sensitivities of all biomarkers were 0.80–0.86, along with pooled specificities of 0.60–0.82, positive predictive values (PPVs) of 0.52–0.80, and negative predictive values (NPVs) of 0.70–0.87. Among them, hs-cTnT had the highest sensitivity (0.86 [95% CI: 0.84–0.88]), specificity (0.82 [95% CI: 0.79–0.84]), PPV (0.80 [95% CI: 0.77–0.83]), and NPV (0.87 [95% CI: 0.85–0.89]), while MR-proADM had the lowest sensitivity (0.80 [95% CI: 0.75–0.84]), specificity (0.60 [95% CI: 0.56–0.64]), and PPV (0.52 [95% CI: 0.47–0.56]). Copeptin had the lowest NPV (0.70 [95% CI: 0.66–0.74]). The positive likelihood ratio (LR+) of all biomarkers ranged from 1.97 to 3.21, and the negative likelihood ratio (LR−) from 0.20 to 0.36. MR-proADM had the lowest LR+ and highest LR−; galectin-3 had the highest LR+ and MR-proANP had the lowest LR−. The area under the curve (AUC) was as low as 0.68 for MR-proADM, while AUCs for the other biomarkers ranged from 0.83 to 0.89.

Conclusion

The overall diagnostic accuracy of copeptin, galectin-3, hs-cTnT, MR-proANP, and ST2 was relatively good. MR-proADM had a poor capacity to confirm or exclude HF. Improving the diagnostic accuracy of HF by a combination of biomarkers could be considered in the future.
Literatur
1.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):1810–1852 PubMed Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):1810–1852 PubMed
2.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14(8):803–869 PubMed McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14(8):803–869 PubMed
3.
Zurück zum Zitat Adams KF Jr, Fonarow GC, Emerman CL et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209–216 PubMed Adams KF Jr, Fonarow GC, Emerman CL et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209–216 PubMed
4.
Zurück zum Zitat Fonarow GC, Abraham WT, Albert NM et al (2004) Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. Am Heart J 148(1):43–51 PubMed Fonarow GC, Abraham WT, Albert NM et al (2004) Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. Am Heart J 148(1):43–51 PubMed
6.
Zurück zum Zitat Delerme S, Ray P (2008) Acute respiratory failure in the elderly: diagnosis and prognosis. Age Ageing 37(3):251–257 PubMed Delerme S, Ray P (2008) Acute respiratory failure in the elderly: diagnosis and prognosis. Age Ageing 37(3):251–257 PubMed
7.
Zurück zum Zitat Wuerz RC, Meador SA (1992) Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 21(6):669–674 PubMed Wuerz RC, Meador SA (1992) Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 21(6):669–674 PubMed
8.
Zurück zum Zitat Bales AC, Sorrentino MJ (1997) Causes of congestive heart failure. Prompt diagnosis may affect prognosis. Postgrad Med 101(1):44–49, 54–56 PubMed Bales AC, Sorrentino MJ (1997) Causes of congestive heart failure. Prompt diagnosis may affect prognosis. Postgrad Med 101(1):44–49, 54–56 PubMed
9.
Zurück zum Zitat Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The N‑terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95(8):948–954 PubMed Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The N‑terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95(8):948–954 PubMed
10.
Zurück zum Zitat Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E et al (2004) N‑terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 6(3):301–308 PubMed Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E et al (2004) N‑terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 6(3):301–308 PubMed
11.
Zurück zum Zitat McCullough PA, Nowak RM, McCord J et al (2002) B‑type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106(4):416–422 PubMed McCullough PA, Nowak RM, McCord J et al (2002) B‑type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106(4):416–422 PubMed
12.
Zurück zum Zitat Wang CS, FitzGerald JM, Schulzer M et al (2005) Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 294(15):1944–1956 PubMed Wang CS, FitzGerald JM, Schulzer M et al (2005) Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 294(15):1944–1956 PubMed
13.
Zurück zum Zitat Ghosh N, Haddad H (2011) Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value. Can J Physiol Pharmacol 89(8):587–591 PubMed Ghosh N, Haddad H (2011) Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value. Can J Physiol Pharmacol 89(8):587–591 PubMed
14.
Zurück zum Zitat Martindale JL, Wakai A, Collins SP et al (2016) Diagnosing acute heart failure in the emergency department: a systematic review and meta-analysis. Acad Emerg Med 23(3):223–242 PubMed Martindale JL, Wakai A, Collins SP et al (2016) Diagnosing acute heart failure in the emergency department: a systematic review and meta-analysis. Acad Emerg Med 23(3):223–242 PubMed
15.
Zurück zum Zitat Maisel AS, Peacock WF, Shah KS et al (2011) Acoustic cardiography S3 detection use in problematic subgroups and B‑type natriuretic peptide “gray zone”: secondary results from the heart failure and Audicor technology for rapid diagnosis and initial treatment multinational investigation. Am J Emerg Med 29(8):924–931 PubMed Maisel AS, Peacock WF, Shah KS et al (2011) Acoustic cardiography S3 detection use in problematic subgroups and B‑type natriuretic peptide “gray zone”: secondary results from the heart failure and Audicor technology for rapid diagnosis and initial treatment multinational investigation. Am J Emerg Med 29(8):924–931 PubMed
16.
Zurück zum Zitat Dieplinger B, Gegenhuber A, Haltmayer M et al (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18):1508–1513 PubMed Dieplinger B, Gegenhuber A, Haltmayer M et al (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18):1508–1513 PubMed
17.
Zurück zum Zitat Qi X, Ding KQ (2011) Changes of the serum NT-proBNP concentration and the serum Copeptin concentration in patient of heart failure. http://​www.​365yixue.​com, W060669, last access: 30 July 2011 Qi X, Ding KQ (2011) Changes of the serum NT-proBNP concentration and the serum Copeptin concentration in patient of heart failure. http://​www.​365yixue.​com, W060669, last access: 30 July 2011
18.
Zurück zum Zitat Yan F, Ren LQ (2012) Evaluating the value of Copeptin in diagnosis of chronic heart failure[D]. Southeast University, Nanjing, pp 1–43 Yan F, Ren LQ (2012) Evaluating the value of Copeptin in diagnosis of chronic heart failure[D]. Southeast University, Nanjing, pp 1–43
19.
Zurück zum Zitat Mason JM, Hancock HC, Close H et al (2013) Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS ONE 8(1):e53560 PubMedPubMedCentral Mason JM, Hancock HC, Close H et al (2013) Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS ONE 8(1):e53560 PubMedPubMedCentral
20.
Zurück zum Zitat Wang LH, Xia F, Chen QS et al (2013) Clinical value of Copeptin for enzyme-linked immunosorbent assay of quantitative detection in diagnosis of heart failure. J Mod Lab Med 28(6):55–62 Wang LH, Xia F, Chen QS et al (2013) Clinical value of Copeptin for enzyme-linked immunosorbent assay of quantitative detection in diagnosis of heart failure. J Mod Lab Med 28(6):55–62
21.
Zurück zum Zitat Sun QW, Chen HQ (2013) The serum Copeptin measurement value in the diagnosis and prognosis of patients with heart failure. Chin Circul J 28(7):51–514 Sun QW, Chen HQ (2013) The serum Copeptin measurement value in the diagnosis and prognosis of patients with heart failure. Chin Circul J 28(7):51–514
22.
Zurück zum Zitat Kim JS, Yang JW, Chai MH et al (2015) Copeptin in hemodialysis patients with left ventricular dysfunction. Yonsei Med J 56(4):976–980 PubMedPubMedCentral Kim JS, Yang JW, Chai MH et al (2015) Copeptin in hemodialysis patients with left ventricular dysfunction. Yonsei Med J 56(4):976–980 PubMedPubMedCentral
23.
Zurück zum Zitat van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48(6):1217–1224 PubMed van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48(6):1217–1224 PubMed
24.
Zurück zum Zitat Zhao Y, Sun YM (2012) The observation between Galectin-3 and coronary heart disease with heart failure[D]. TianJin medical university, TianJin, pp 1–31 Zhao Y, Sun YM (2012) The observation between Galectin-3 and coronary heart disease with heart failure[D]. TianJin medical university, TianJin, pp 1–31
25.
Zurück zum Zitat Chen K, Jiang RJ, Wang CQ et al (2013) Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci 17(8):1005–1011 PubMed Chen K, Jiang RJ, Wang CQ et al (2013) Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci 17(8):1005–1011 PubMed
26.
Zurück zum Zitat Geng FQ, Yang P (2014) Diagnostic and predictive value of serum Galectin-3 in patients with chronic heart failure[D]. JiLin university, JiLin, pp 1–21 Geng FQ, Yang P (2014) Diagnostic and predictive value of serum Galectin-3 in patients with chronic heart failure[D]. JiLin university, JiLin, pp 1–21
27.
Zurück zum Zitat Yin QS, Shi B, Dong L et al (2014) Comparative study of galectin-3 and B‑type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 11(1):79–82 PubMedPubMedCentral Yin QS, Shi B, Dong L et al (2014) Comparative study of galectin-3 and B‑type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 11(1):79–82 PubMedPubMedCentral
28.
Zurück zum Zitat Shi B, Xue DW (2015) Diagnostic and predictive value of plasma Galectin-3 in elderly patients with heart failure with reserved ejection fraction. Chin J Geriatr Heart Brain Vessel Dis 17(9):980–982 Shi B, Xue DW (2015) Diagnostic and predictive value of plasma Galectin-3 in elderly patients with heart failure with reserved ejection fraction. Chin J Geriatr Heart Brain Vessel Dis 17(9):980–982
29.
Zurück zum Zitat Polat V, Bozcali E, Uygun T et al (2016) Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol 71(2):191–197 PubMed Polat V, Bozcali E, Uygun T et al (2016) Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol 71(2):191–197 PubMed
30.
Zurück zum Zitat Zhang X, Wan Y, Chata R et al (2016) A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva. J Clin Pathol 69(12):1100–1104 PubMed Zhang X, Wan Y, Chata R et al (2016) A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva. J Clin Pathol 69(12):1100–1104 PubMed
31.
Zurück zum Zitat Wang AY, Lam CW, Wang M et al (2009) Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant 24(6):1962–1969 PubMed Wang AY, Lam CW, Wang M et al (2009) Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant 24(6):1962–1969 PubMed
32.
Zurück zum Zitat Kitagawa M, Sugiyama H, Morinaga H et al (2011) Serum high-sensitivity cardiac troponin T is a significant biomarker of left-ventricular diastolic dysfunction in subjects with non-diabetic chronic kidney disease. Nephron Extra 1(1):166–177 PubMedPubMedCentral Kitagawa M, Sugiyama H, Morinaga H et al (2011) Serum high-sensitivity cardiac troponin T is a significant biomarker of left-ventricular diastolic dysfunction in subjects with non-diabetic chronic kidney disease. Nephron Extra 1(1):166–177 PubMedPubMedCentral
33.
Zurück zum Zitat Takashio S, Yamamuro M, Izumiya Y et al (2013) Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J Am Coll Cardiol 62(7):632–640 PubMed Takashio S, Yamamuro M, Izumiya Y et al (2013) Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J Am Coll Cardiol 62(7):632–640 PubMed
34.
Zurück zum Zitat Eindhoven JA, Roos-Hesselink JW, van den Bosch AE et al (2015) High-sensitive troponin-T in adult congenital heart disease. Int J Cardiol 184:405–411 PubMed Eindhoven JA, Roos-Hesselink JW, van den Bosch AE et al (2015) High-sensitive troponin-T in adult congenital heart disease. Int J Cardiol 184:405–411 PubMed
35.
Zurück zum Zitat Rybicka J, Dobrowolski P, Lipczyńska M et al (2015) High sensitivity troponin T in adult congenital heart disease. Int J Cardiol 195:7–14 PubMed Rybicka J, Dobrowolski P, Lipczyńska M et al (2015) High sensitivity troponin T in adult congenital heart disease. Int J Cardiol 195:7–14 PubMed
36.
Zurück zum Zitat Daquarti G, March Vecchio N, Mitrione CS et al (2016) High-sensitivity troponin and right ventricular function in acute pulmonary embolism. Am J Emerg Med 34(8):1579–1582 PubMed Daquarti G, March Vecchio N, Mitrione CS et al (2016) High-sensitivity troponin and right ventricular function in acute pulmonary embolism. Am J Emerg Med 34(8):1579–1582 PubMed
37.
Zurück zum Zitat Sun L, Tan X, Cao X et al (2016) Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients. Ren Fail 38(5):728–737 PubMed Sun L, Tan X, Cao X et al (2016) Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients. Ren Fail 38(5):728–737 PubMed
38.
Zurück zum Zitat Elmas E, Lang S, Dempfle CE et al (2008) Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int J Cardiol 128(1):107–111 PubMed Elmas E, Lang S, Dempfle CE et al (2008) Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int J Cardiol 128(1):107–111 PubMed
39.
Zurück zum Zitat Cinar O, Cevik E, Acar A et al (2012) Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients. Am J Emerg Med 30(9):1915–1920 PubMed Cinar O, Cevik E, Acar A et al (2012) Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients. Am J Emerg Med 30(9):1915–1920 PubMed
40.
Zurück zum Zitat Gegenhuber A, Struck J, Poelz W et al (2006) Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B‑type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 52(5):827–831 PubMed Gegenhuber A, Struck J, Poelz W et al (2006) Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B‑type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 52(5):827–831 PubMed
41.
Zurück zum Zitat Elmas E, Brueckmann M, Lang S et al (2008) Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Int J Cardiol 128(2):244–249 PubMed Elmas E, Brueckmann M, Lang S et al (2008) Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Int J Cardiol 128(2):244–249 PubMed
42.
Zurück zum Zitat Moertl D, Berger R, Struck J et al (2009) Comparison of midregional pro-atrial and B‑type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53(19):1783–1790 PubMed Moertl D, Berger R, Struck J et al (2009) Comparison of midregional pro-atrial and B‑type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53(19):1783–1790 PubMed
43.
Zurück zum Zitat Maisel A, Mueller C, Nowak R et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55(19):2062–2076 PubMed Maisel A, Mueller C, Nowak R et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55(19):2062–2076 PubMed
44.
Zurück zum Zitat Potocki M, Breidthardt T, Reichlin T et al (2010) Comparison of midregional pro-atrial natriuretic peptide with N‑terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 267(1):119–129 PubMed Potocki M, Breidthardt T, Reichlin T et al (2010) Comparison of midregional pro-atrial natriuretic peptide with N‑terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 267(1):119–129 PubMed
45.
Zurück zum Zitat Daniels LB, Clopton P, Potocki M et al (2012) Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 14(1):22–31 PubMed Daniels LB, Clopton P, Potocki M et al (2012) Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 14(1):22–31 PubMed
46.
Zurück zum Zitat Eckstein J, Potocki M, Murray K et al (2012) Direct comparison of mid-regional pro-atrial natriuretic peptide with N‑terminal pro B‑type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea. Heart 98(20):1518–1522 PubMed Eckstein J, Potocki M, Murray K et al (2012) Direct comparison of mid-regional pro-atrial natriuretic peptide with N‑terminal pro B‑type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea. Heart 98(20):1518–1522 PubMed
47.
Zurück zum Zitat Shah RV, Truong QA, Gaggin HK et al (2012) Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33(17):2197–2205 PubMedPubMedCentral Shah RV, Truong QA, Gaggin HK et al (2012) Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33(17):2197–2205 PubMedPubMedCentral
48.
Zurück zum Zitat Richards M, Di Somma S, Mueller C et al (2013) Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). Jacc Heart Fail 1(3):192–199 PubMed Richards M, Di Somma S, Mueller C et al (2013) Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). Jacc Heart Fail 1(3):192–199 PubMed
49.
Zurück zum Zitat Hauser JA, Demyanets S, Rusai K et al (2016) Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart 102(20):1633–1639 PubMed Hauser JA, Demyanets S, Rusai K et al (2016) Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart 102(20):1633–1639 PubMed
50.
Zurück zum Zitat Heining L, Giesa C, Ewig S (2016) MR-proANP, MR-proADM, and PCT in patients presenting with acute dyspnea in a medical emergency unit. Lung 194(2):185–191 PubMed Heining L, Giesa C, Ewig S (2016) MR-proANP, MR-proADM, and PCT in patients presenting with acute dyspnea in a medical emergency unit. Lung 194(2):185–191 PubMed
51.
Zurück zum Zitat Aldous SJ, Richards AM, Troughton R et al (2012) ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 18(4):304–310 PubMed Aldous SJ, Richards AM, Troughton R et al (2012) ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 18(4):304–310 PubMed
52.
Zurück zum Zitat Yuan W, Gu YY, Zhang DF (2012) Measurement of serum soluble ST2 in patients with heart failure and its disagnostic value. Acad J Second Mil Med Univ 33(2):175–178 Yuan W, Gu YY, Zhang DF (2012) Measurement of serum soluble ST2 in patients with heart failure and its disagnostic value. Acad J Second Mil Med Univ 33(2):175–178
53.
Zurück zum Zitat Di YQ, Peng DQ (2013) Role of soluble ST2 in the diagnosis of heart failure. Chin J Cardiovasc Med 18(5):334–338 Di YQ, Peng DQ (2013) Role of soluble ST2 in the diagnosis of heart failure. Chin J Cardiovasc Med 18(5):334–338
54.
Zurück zum Zitat Huang CH, Shen J, Ma XW, al et (2013) Diagnostic value of serum sST2 for left ventricular diastolic dysfunction in patients with type 2 diabetes. Chin J Clin 7(6):2350–2354 Huang CH, Shen J, Ma XW, al et (2013) Diagnostic value of serum sST2 for left ventricular diastolic dysfunction in patients with type 2 diabetes. Chin J Clin 7(6):2350–2354
55.
Zurück zum Zitat Wang YC, Yu CC, Chiu FC et al (2013) Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 19(3):163–168 PubMed Wang YC, Yu CC, Chiu FC et al (2013) Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 19(3):163–168 PubMed
56.
Zurück zum Zitat Wen JL, Cui XY, Chen FY (2013) Correlation analysis of N‑terminal brain natriuretic peptide, brain natriuretic peptide and ST2 with heart failure severity. China Med Her 10(2):76–80 Wen JL, Cui XY, Chen FY (2013) Correlation analysis of N‑terminal brain natriuretic peptide, brain natriuretic peptide and ST2 with heart failure severity. China Med Her 10(2):76–80
57.
Zurück zum Zitat Yang Y, Luo Y (2013) The clinical significance of B‑type natriuretic peptide, N‑terminal pronatriuretic peptide and soluble ST2 monitoring in patients with heart failure. Guangdong Med J 34(13):2022–2026 Yang Y, Luo Y (2013) The clinical significance of B‑type natriuretic peptide, N‑terminal pronatriuretic peptide and soluble ST2 monitoring in patients with heart failure. Guangdong Med J 34(13):2022–2026
58.
Zurück zum Zitat Dai Q, Wu J, Guo W et al (2014) The performance evaluation of soluble ST2 detection kit and the clinical application of sST2 in diagnosing heart failure. Chin J Lab Med 37(5):394–398 Dai Q, Wu J, Guo W et al (2014) The performance evaluation of soluble ST2 detection kit and the clinical application of sST2 in diagnosing heart failure. Chin J Lab Med 37(5):394–398
59.
Zurück zum Zitat Ding B, Song JP (2014) The role of IL-33 and sST2 in diagnosing heart failure[D]. Soochow university, JiangSu, pp 1–39 Ding B, Song JP (2014) The role of IL-33 and sST2 in diagnosing heart failure[D]. Soochow university, JiangSu, pp 1–39
60.
Zurück zum Zitat Ding HF, Sun L, Tian ST et al (2015) Changes and clinical significances of BNP, NT-proBNP and sST2 in patients with heart failure. PJCCPVD 23(6):16–18 Ding HF, Sun L, Tian ST et al (2015) Changes and clinical significances of BNP, NT-proBNP and sST2 in patients with heart failure. PJCCPVD 23(6):16–18
61.
Zurück zum Zitat Yang FT, Su BF, Zhan X et al (2015) Correlation between serum soluble ST2 and BNP in patients with heart failure. J Mod Lab Med 30(6):78–79 Yang FT, Su BF, Zhan X et al (2015) Correlation between serum soluble ST2 and BNP in patients with heart failure. J Mod Lab Med 30(6):78–79
62.
Zurück zum Zitat Yang W, Han HY, Pan YH et al (2016) Clinical research about B‑brain natriuretci peptide, soluble ST2 and interleukin 33 in patients with heart failure. Chin J Microcirc 26(1):45–48, 52 Yang W, Han HY, Pan YH et al (2016) Clinical research about B‑brain natriuretci peptide, soluble ST2 and interleukin 33 in patients with heart failure. Chin J Microcirc 26(1):45–48, 52
63.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. Circulation 126(16):2020–2035 PubMed Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. Circulation 126(16):2020–2035 PubMed
64.
Zurück zum Zitat Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536 PubMed Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536 PubMed
65.
Zurück zum Zitat Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12(14):1293–1316 PubMed Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12(14):1293–1316 PubMed
67.
Zurück zum Zitat Januzzi JL Jr, Chen-Tournoux AA, Moe G (2008) Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 101(3A):29–38 PubMed Januzzi JL Jr, Chen-Tournoux AA, Moe G (2008) Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 101(3A):29–38 PubMed
68.
Zurück zum Zitat Worster A, Balion CM, Hill SA et al (2008) Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem 41(4–5):250–259 PubMed Worster A, Balion CM, Hill SA et al (2008) Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem 41(4–5):250–259 PubMed
69.
Zurück zum Zitat Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240(4857):1285–1293 PubMed Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240(4857):1285–1293 PubMed
70.
Zurück zum Zitat Hill SA, Booth RA, Santaguida PL et al (2014) Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev 19(4):421–438 PubMed Hill SA, Booth RA, Santaguida PL et al (2014) Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev 19(4):421–438 PubMed
71.
Zurück zum Zitat Peacock WF (2014) Novel biomarkers in acute heart failure: MR-pro-adrenomedullin. Clin Chem Lab Med 52(10):1433–1435 PubMed Peacock WF (2014) Novel biomarkers in acute heart failure: MR-pro-adrenomedullin. Clin Chem Lab Med 52(10):1433–1435 PubMed
72.
Zurück zum Zitat Potocki M, Ziller R, Mueller C (2012) Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep 9(3):244–251 PubMed Potocki M, Ziller R, Mueller C (2012) Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep 9(3):244–251 PubMed
73.
Zurück zum Zitat Zhan ST, Tan HZ, Sun YH (2015) Clinical epidemiology, 3rd edn. People’s Medical Publishing House, Beijing, pp 106–118 Zhan ST, Tan HZ, Sun YH (2015) Clinical epidemiology, 3rd edn. People’s Medical Publishing House, Beijing, pp 106–118
74.
Zurück zum Zitat Hu Z, Han Z, Huang Y et al (2012) Diagnostic power of the mid-regional pro-atrial natriuretic peptide for heart failure patients with dyspnea: a meta-analysis. Clin Biochem 45(18):1634–1639 PubMed Hu Z, Han Z, Huang Y et al (2012) Diagnostic power of the mid-regional pro-atrial natriuretic peptide for heart failure patients with dyspnea: a meta-analysis. Clin Biochem 45(18):1634–1639 PubMed
75.
Zurück zum Zitat van Kimmenade RR, Januzzi JL Jr, Bakker JA et al (2009) Renal clearance of B‑type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53(10):884–890 PubMed van Kimmenade RR, Januzzi JL Jr, Bakker JA et al (2009) Renal clearance of B‑type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53(10):884–890 PubMed
76.
Zurück zum Zitat Kim MS, Jeong TD, Han SB et al (2015) Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J Korean Med Sci 30(5):569–575 PubMedPubMedCentral Kim MS, Jeong TD, Han SB et al (2015) Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J Korean Med Sci 30(5):569–575 PubMedPubMedCentral
77.
Zurück zum Zitat Bayes-Genis A, Zamora E, de Antonio M et al (2013) Soluble ST2 serum concentration and renal function in heart failure. J Card Fail 19(11):768–775 PubMed Bayes-Genis A, Zamora E, de Antonio M et al (2013) Soluble ST2 serum concentration and renal function in heart failure. J Card Fail 19(11):768–775 PubMed
78.
Zurück zum Zitat Chung JZ, Jones DGR (2015) Effect of renal function on serum cardiac troponin T—Population and individual effects. Clin Biochem 48(12):807–810 PubMed Chung JZ, Jones DGR (2015) Effect of renal function on serum cardiac troponin T—Population and individual effects. Clin Biochem 48(12):807–810 PubMed
79.
Zurück zum Zitat Ponte B, Pruijm M, Ackermann D et al (2015) Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol 26(6):1415–1425 PubMed Ponte B, Pruijm M, Ackermann D et al (2015) Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol 26(6):1415–1425 PubMed
80.
Zurück zum Zitat Zamora E, Lupón J, de Antonio M et al (2014) Renal function largely influences galectin-3 prognostic value in heart failure. Int J Cardiol 177(1):171–177 PubMed Zamora E, Lupón J, de Antonio M et al (2014) Renal function largely influences galectin-3 prognostic value in heart failure. Int J Cardiol 177(1):171–177 PubMed
81.
Zurück zum Zitat Chenevier-Gobeaux C, Guerin S, André S et al (2010) Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B‑type natriuretic peptide (BNP) and N‑terminal proBNP. Clin Chem 56(11):1708–1717 PubMed Chenevier-Gobeaux C, Guerin S, André S et al (2010) Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B‑type natriuretic peptide (BNP) and N‑terminal proBNP. Clin Chem 56(11):1708–1717 PubMed
82.
Zurück zum Zitat Lok DJ, Lok SI, Bruggink-André de la Porte PW et al (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102(2):103–110 PubMed Lok DJ, Lok SI, Bruggink-André de la Porte PW et al (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102(2):103–110 PubMed
83.
Zurück zum Zitat Stolen CM, Adourian A, Meyer TE et al (2014) Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail 20(11):793–799 PubMed Stolen CM, Adourian A, Meyer TE et al (2014) Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail 20(11):793–799 PubMed
84.
Zurück zum Zitat Ky B, French B, McCloskey K et al (2011) High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4(2):180–187 PubMed Ky B, French B, McCloskey K et al (2011) High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4(2):180–187 PubMed
Metadaten
Titel
Diagnostic value of novel biomarkers for heart failure
A meta-analysis
verfasst von
Z. Huang
J. Zhong
Y. Ling
Y. Zhang
W. Lin
L. Tang
J. Liu
S. Li
Publikationsdatum
26.04.2018
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-018-4702-6